Allurion Technologies Inc (ALUR) Actualités

Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program

Average weight reduction in 486 patients improved from 10.5% at four months to 13.7% at one year on the Allurion Program Separate studies with...

Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial

Mr. Wild brings over 20 years of experience building profitable commercial organizations at leading healthcare brands Allurion Technologies, Inc...

Allurion Receives Continued Listing Standards Notice from NYSE

Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received...

Allurion Reports Second Quarter 2024 Financial Results and Provides Business Update

Results highlighted by strong sequential revenue growth and record procedure volume Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the...

Allurion suspend les ventes et retire l'approvisionnement du Ballon Allurion en France jusqu’à la mise en œuvre d'un plan de réduction des risques

Allurion Technologies, Inc. (NYSE: ALUR), une entreprise qui s’est donné pour objectif de combattre l’obésité, a annoncé aujourd'hui avoir...

Allurion to Report Second Quarter 2024 Financial Results on August 13, 2024

Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will...

Allurion Announces Pricing of $20 million Public Offering and Concurrent Private Placement

Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced the pricing of an...

Allurion Announces Launch of Offering of Common Stock and Warrants

Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it has...

Allurion Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight Loss

Patients gained an average of 5.6% in lean body mass during the Allurion Program Separate studies of patients on GLP-1 therapy report an average...

Allurion Announces Three Scientific Presentations at the 40th Annual Meeting of the American Society for Metabolic and Bariatric Surgery

New data show 22.1% weight loss at one year with consecutive Allurion Balloons, approaching weight loss surgery outcomes Allurion Technologies...

Form 4 - Statement of changes in beneficial ownership of securities

Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer

Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief...

Allurion Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s

Company also announces first commercial agreements for the Virtual Care Suite in the United States Allurion Technologies, Inc. (NYSE: ALUR), a...

Allurion to Participate in Two Upcoming Investor Conferences in June 2024

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in two upcoming...

Allurion Announces Three Scientific Presentations at the European Congress on Obesity, Including Study on Lean Mass Preservation for Sustainable, Healthy Weight Loss

New data demonstrate significant fat mass loss while preserving lean mass Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending...